Neuromapping techniques in drug discovery: Pharmacological MRI for the assessment of novel antipsychotics

Expert Opinion on Drug Discovery

Volumn 7, Issue 11, 2012, Pages 1071-1082

  Bifone, Angelo ^a   Gozzi, Alessandro ^a  

^a CENTER FOR NANOTECHNOLOGY INNOVATION NEST   (Italy)

Author keywords

Antipsychotics; Brain; FMRI; Ketamine; MGluR2 3; NMDA receptors; Phencyclidine; PhMRI

Indexed keywords

CLOZAPINE; DIZOCILPINE; EGLUMETAD; GLUTAMIC ACID; KETAMINE; LAMOTRIGINE; N ACETYLASPARTYLGLUTAMIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEUROLEPTIC AGENT; PHENCYCLIDINE; RISPERIDONE;

BOLD SIGNAL; BRAIN BLOOD FLOW; BRAIN MAPPING; CEREBROSPINAL FLUID; COGNITIVE DEFECT; CONSTRUCT VALIDITY; ELECTROENCEPHALOGRAPHY; FUNCTIONAL MAGNETIC RESONANCE IMAGING; FUNCTIONAL NEUROIMAGING; GENERAL ANESTHESIA; GLUTAMATERGIC NEUROTRANSMISSION; HUMAN; MAGNETOENCEPHALOGRAPHY; NERVE CONDUCTION; NEUROTRANSMISSION; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA; SINGLE DRUG DOSE;

CENTRAL NERVOUS SYSTEM; CENTRAL NERVOUS SYSTEM AGENTS; CENTRAL NERVOUS SYSTEM DISEASES; DRUG DISCOVERY; HUMANS; MAGNETIC RESONANCE IMAGING;

EID: 84867920851     PISSN: 17460441     EISSN: 1746045X     Source Type: Journal    
DOI: 10.1517/17460441.2012.724057     Document Type: Review

References (86)

1. Pammolli F, Magazzini L, Riccaboni M. The productivity crisis in pharmaceutical R&D. Nat Rev Drug Discov 2011;10:428-38; 10.1038/nrd3405
2. Ogawa S, Lee TM, Kay AR, Tank DW. Brain magnetic resonance imaging with contrast dependent on blood oxygenation. Proc Nat Acad Sci USA 1990;87:9868-72 (Pubitemid 120016545)
3. Mosso A. Ueber den Kreislauf des Blutes im menschlichen Gehirn. 1881
4. Roy CS, Sherrington CS. On the regulation of the blood-supply of the brain. J Physiol 1890;11:85-158
5. Kwong KK, Belliveau JW, Chesler DA, et al. Dynamic magnetic resonance imaging of human brain activity during primary sensory stimulation. Proc Nat Acad Sci USA 1992;89:5675-9
6. Bandettini PA, Wong EC, Hinks RS, et al. Time course EPI of human brain function during task activation. Magn Reson Med 1992;25:390-7
7. Frahm J, Bruhn H, Merbolt K, Hanicke W. Dynamic MR imaging of human brain oxygenation during rest and photic stimulation. Magn Reson Imag 1992;2:501-5
8. Gottesman II, Gould TD. The endophenotype concept in psychiatry: etymology and strategic intentions. Am J Psychiatry 2003;160:636-45 (Pubitemid 41079594)
9. Large CH, Bison S, Sartori I, et al. The efficacy of sodium channel blockers to prevent PCP-induced cognitive dysfunction in the rat: Potential for novel treatments for schizophrenia. J Pharmacol Exp Ther 2011;338(1):100-13
10. Chen CH, Ridler K, Suckling J, et al. Brain imaging correlates of depressive symptom severity and predictors of symptom improvement after antidepressant treatment. Biol Psychiatry 2007;62:407-14 (Pubitemid 47284016)
11. Pezawas L, Meyer-Lindenberg A, Drabant EM, et al. 5-HTTLPR polymorphism impacts human cingulate-amygdala interactions: a genetic susceptibility mechanism for depression. Nat Neurosci 2005;8:828-34 (Pubitemid 43085851)
12. Sheline YI, Barch DM, Donnelly JM, et al. Increased amygdala response to masked emotional faces in depressed subjects resolves with antidepressant treatment: an fMRI study. Biol Psychiatry 2001;50:651-8 (Pubitemid 33043767)
13. Fu CH, Williams SC, Cleare AJ, et al. Attenuation of the neural response to sad faces in major depression by antidepressant treatment: a prospective, event-related functional magnetic resonance imaging study. Arch Gen Psychiatry 2004;61:877-89 (Pubitemid 39181077)
14. Leslie RA, James MF. Pharmacological magnetic resonance imaging: a new application for functional MRI. Trends Pharmacol Sci 2000;21:314-18 (Pubitemid 30642922)
15. Javitt DC, Schoepp D, Kalivas PW, et al. Translating Glutamate: from Pathophysiology to Treatment. Sci Transl Med 2011;3:102mr2
16. Krystal JH, Karper LP, Seibyl JP, et al. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 1994;51:199-214 (Pubitemid 24081509)
17. Luby ED, Cohen BD, Rosenbaum G, et al. Study of a new schizophrenic-like drug: sernyl. Arch Neurol Psychiat 1959;81:363-9
18. Javitt DC, Zukin SR. Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 1991;148:1301-8
19. Kristiansen LV, Huerta I, Beneyto M, Meador-Woodruff JH. NMDA receptors and schizophrenia. Curr Opin Pharmacol 2007;7:48-55
20. Tsai SJ. Central N-acetyl aspartylglutamate deficit: a possible pathogenesis of schizophrenia. Med Sci Monit 2005;11:HY39-45; 7071 [pii]
21. Linderholm KR, Skogh E, Olsson SK, et al. Increased levels of kynurenine and kynurenic acid in the CSF of patients with schizophrenia. Schizophr Bull 2012;38(3):426-32
22. Hashimoto K, Engberg G, Shimizu E, et al. Reduced d-serine to total serine ratio in the cerebrospinal fluid of drug naive schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatry 2005;29:767-9 (Pubitemid 40897791)
23. Bendikov I, Nadri C, Amar S, et al. A CSF and postmortem brain study of d-serine metabolic parameters in schizophrenia. Schizophr Res 2007;90:41-51 (Pubitemid 46177566)
24. Madeira C, Freitas ME, Vargas-Lopes C, Wolosker H. Panizzutti Rr. Increased brain d-amino acid oxidase (DAAO) activity in schizophrenia. Schizophr Res 2008;101:76-83
25. Do KQ, Cabungcal JH, Frank A, et al. Redox dysregulation, neurodevelopment, and schizophrenia. Curr Opin Neurobiol 2009;19:220-30
26. Large CH. Do NMDA receptor antagonist models of schizophrenia predict the clinical efficacy of antipsychotic drugs? J Psychopharmacol 2007;21:283-301
27. Gozzi A, Herdon H, Schwarz A, et al. Pharmacological stimulation of NMDA receptors via co-agonist site suppresses fMRI response to phencyclidine in the rat. Psychopharmacology (Berl) 2008;201:273-84
28. Gozzi A, Crestan V, Turrini G, et al. Antagonism at serotonin 5-HT2A receptors modulates functional activity of fonto-hippocampal circuit. Psychopharmacology (Berl) 2010;209:37-50
29. Littlewood CL, Diana C, Dixon AL, et al. Using the BOLD MR signal to differentiate the stereoisomers of ketamine in the rat. Neuroimage 2006;32:1733-46 (Pubitemid 44332281)
30. Gozzi A, Schwarz AJ, Reese T, et al. Drug-anaesthetic interaction in phMRI: the case of the pyschotomimetic agent phencyclidine. Magn Reson Imag 2008;26:999-1006
31. Gozzi A, Large C, Schwarz A, et al. differential effects of antipsychotic and glutamatergic agents on the phmri response to phencyclidine. Neuropsychopharmacology 2008;33:1690-703 (Pubitemid 351684709)
32. Chin CL, Upadhyay J, Marek GJ, et al. Awake rat pharmacological MRI as a translational pharmacodynamic biomarker: mGluR2/3 agonist modulation of ketamine-induced BOLD signals. J Pharmacol Exp Ther 2011;336(3):709-15
33. Risterucci C, Jeanneau K, Schoppenthau S, et al. Functional magnetic resonance imaging reveals similar brain activity changes in two different animal models of schizophrenia. Psychopharmacology (Berl) 2005;180:724-34 (Pubitemid 41317868)
34. Fitzgerald PJ. The NMDA receptor may participate in widespread suppression of circuit level neural activity, in addition to a similarly prominent role in circuit level activation. Behav Brain Res 2012;230:291-8
35. Morris BJ, Cochran SM, Pratt JA. PCP: from pharmacology to modelling schizophrenia. Curr Opin Pharmacol 2005;5:101-6 (Pubitemid 40124542)
36. Hodkinson DJ, de Groote C, McKie S, et al. Differential Effects of Anaesthesia on the phMRI Response to Acute Ketamine Challenge. Br J Med Med Res 2012;2:373-85
37. Roberts TJ, Williams SCR, Modo M. A pharmacological MRI assessment of dizocilpine (MK-801) in the 3-nitroproprionic acid-lesioned rat. Neurosci Lett 2008;444:42-7
38. Duncan GE, Moy SS, Knapp DJ, et al. Metabolic mapping of the rat brain after subanesthetic doses of ketamine: potential relevance to schizophrenia. Brain Res 1998;787:181-90 (Pubitemid 28197904)
39. Duncan GE, Zorn S, Lieberman JA. Mechanisms of typical and atypical antipsychotic drug action in relation to dopamine and NMDA receptor hypofunction hypotheses of schizophrenia. Mol Psychiatry 1999;4:418-28 (Pubitemid 29497729)
40. Duncan GE, Leipzig JN, Mailman RB, Lieberman JA. Differential effects of clozapine and haloperidol on ketamine-induced brain metabolic activation. Brain Res 1998;812:65-75 (Pubitemid 29005332)
41. Miyamoto S, Leipzig JN, Lieberman JA, Duncan GE. Effects of ketamine, MK-801, and amphetamine on regional brain 2-deoxyglucose uptake in freely moving mice. Neuropsychopharmacology 2000;22:400-12 (Pubitemid 30105768)
42. Homayoun H, Jackson ME, Moghaddam B. Activation of metabotropic glutamate 2/3 receptors reverses the effects of NMDA receptor hypofunction on prefrontal cortex unit activity in awake rats. J Neurophysiol 2005;93:1989-2001 (Pubitemid 40404399)
43. Cavazzuti M, Porro CA, Biral GP, et al. Ketamine effects on local cerebral blood flow and metabolism in the rat. J Cereb Blood Flow Metab 1987;7:806-11 (Pubitemid 18029825)
44. Nakki R, Sharp FR, Sagar SM, Honkaniemi J. Effects of phencyclidine on immediate early gene expression in the brain. J Neurosci Res 1996;45:13-27 (Pubitemid 26242073)
45. Deakin JFW, Lees J, McKie S, et al. Glutamate and the neural basis of the subjective effects of ketamine: A pharmaco-magnetic resonance imaging study. Arch Gen Psychiatry 2008;65:154-64 (Pubitemid 351214314)
46. Langsjo JW, Kaisti KK, Aalto S, et al. Effects of subanesthetic doses of ketamine on regional cerebral blood flow, oxygen consumption, and blood volume in humans. Anesthesiology 2003;99:614-23 (Pubitemid 37051976)
47. Silbersweig DA, Stern E, Frith C, et al. A functional neuroanatomy of hallucinations in schizophrenia. Nature 1995;378:176-9
48. Liddle PF, Lane CJ, Ngan E. Immediate effects of risperidone on cortico-striato-thalamic loops and the hippocampus. Br J Psychiatry 2000;177:402-7
49. Parellada E, Catafau AM, Bernardo M, et al. Prefrontal dysfunction in young acute neuroleptic-naive schizophrenic patients: a resting and activation SPECT study. Psychiatry Res 1994;55:131-9 (Pubitemid 24301594)
50. Ngan ETC, Lane CJ, Ruth TJ, Liddle PF. Immediate and delayed effects of risperidone on cerebral metabolism in neuroleptic naive schizophrenic patients: correlations with symptom change. J Neurol Neurosurg Psychiatry 2002;72:106-10 (Pubitemid 34073105)
51. Soyka M, Koch W, Moller H, et al. Hypermetabolic pattern in frontal cortex and other brain regions in unmedicated schizophrenia patients. Eur Arch Psychiatry Clin Neurosci 2005;255:308-12 (Pubitemid 41618802)
52. Mitelman SA, Shihabuddin L, Brickman AM, et al. Volume of the cingulate and outcome in schizophrenia. Schizophr Res 2005;72:91-108 (Pubitemid 39550981)
53. Kircher TT, Thienel R. Functional brain imaging of symptoms and cognition in schizophrenia. Prog Brain Res 2005;150:299-308 (Pubitemid 41381561)
54. Clinton SM, Meador-Woodruff JH. Thalamic dysfunction in schizophrenia: neurochemical, neuropathological, and in vivo imaging abnormalities. Schizophr Res 2004;69:237-53 (Pubitemid 38721422)
55. Carlsson A, Waters N, Carlsson ML. Neurotransmitter interactions in schizophrenia-therapeutic implications. Biol Psychiatry 1999;46:1388-95
56. Javitt DC. Glycine transport inhibitors for the treatment of schizophrenia: symptom and disease modification. Curr Opin Drug Discov Devel 2009;12:468-78
57. Depoortere R, Dargazanli G, Estenne-Bouhtou G, et al. Neurochemical, electrophysiological and pharmacological profiles of the selective inhibitor of the glycine transporter-1 SSR504734, a potential new type of antipsychotic. Neuropsychopharmacology 2005;30:1963-85 (Pubitemid 43093498)
58. D'Souza DC, Singh N, Elander J, et al. Glycine transporter inhibitor attenuates the psychotomimetic effects of ketamine in healthy males: preliminary evidence. Neuropsychopharmacology 2012;37:1036-46
59. Tsai GE, Lin PY. Strategies to enhance N-methyl-D-aspartate receptor-mediated neurotransmission in schizophrenia, a critical review and meta-analysis. Curr Pharm Des 2010;16:522-37; CPD-Guochuan E. Tsai (Albert Adell) [pii]
60. Moghaddam B, Javitt D. From revolution to evolution: the glutamate hypothesis of schizophrenia and its implication for treatment. Neuropsychopharmacology 2012;37:4-15
61. Swanson CJ, Bures M, Johnson MP, et al. Metabotropic glutamate receptors as novel targets for anxiety and stress disorders. Nat Rev Drug Discov 2005;4:131-44 (Pubitemid 40277494)
62. Javitt DC. Glutamate as a therapeutic target in psychiatric disorders. Mol Psychiatry 2004;9:984-97 (Pubitemid 39524288)
63. Moghaddam B, Adams BW. Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats. Science 1998;281:1349-52 (Pubitemid 28406826)
64. Cartmell J, Monn JA, Schoepp DD. The metabotropic glutamate 2/3 receptor agonists LY354740 and LY379268 selectively attenuate phencyclidine versus d-amphetamine motor behaviors in rats. J Pharmacol Exp Ther 1999;291:161-70 (Pubitemid 29451586)
65. Schoepp DD, Marek GJ. Preclinical pharmacology of mGlu2/3 receptor agonists: novel agents for schizophrenia? Curr Drug Targets CNS Neurol Disord 2002;1:215-25
66. Krystal JH, Abi-Saab W, Perry E, et al. Preliminary evidence of attenuation of the disruptive effects of the NMDA glutamate receptor antagonist, ketamine, on working memory by pretreatment with the group II metabotropic glutamate receptor agonist, LY354740, in healthy human subjects. Psychopharmacology (Berl) 2005;179:303-9 (Pubitemid 40576718)
67. Patil ST, Zhang L, Martenyi F, et al. Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial. Nat Med 2007;13:1102-7 (Pubitemid 47517511)
68. Kinon BJ, Zhang L, Williams JE, et al. LY2140023 monohydrate: an agonist at the mglu2/3 receptor for the Treatment of Schizophrenia. Schizophr Res 2010;117:379
69. Idris NF, Repeto P, Neill JC, Large CH. Investigation of the effects of lamotrigine and clozapine in improving reversal-learning impairments induced by acute phencyclidine and D-amphetamine in the rat. Psychopharmacology (Berl) 2005;179:336-48
70. Gaisler-Salomon I, Weiner I. Systemic administration of MK-801 produces an abnormally persistent latent inhibition which is reversed by clozapine but not haloperidol. Psychopharmacology 2003;V166:333-42 (Pubitemid 36469935)
71. Linn S, Negi S, Gerum V, Javitt C. Reversal of phencyclidine-induced prepulse inhibition deficits by clozapine in monkeys. Psychopharmacology 2003;V169:234-9 (Pubitemid 37255515)
72. Qiao H, Noda Y, Kamei H, et al. Clozapine, but not haloperidol, reverses social behavior deficit in mice during withdrawal from chronic phencyclidine treatment. Neuroreport 2001;12:11-15 (Pubitemid 32099018)
73. Malhotra AK, Adler CM, Kennison SD, et al. Clozapine Blunts N-Methyl-Aspartate Antagonist-Induced Psychosis: a Study with Ketamine. Biol Psychiatry 1997;42:664-8 (Pubitemid 27444500)
74. Kegeles LS, Martinez D, Kochan LD, et al. NMDA antagonist effects on striatal dopamine release: positron emission tomography studies in humans. Synapse 2002;43:19-29 (Pubitemid 33115664)
75. Meltzer HY. Pre-clinical pharmacology of atypical antipsychotic drugs: a selective review. Br J Psychiatry 1996(Suppl):23-31 (Pubitemid 26181864)
76. Medoff DR, Holcomb HH, Lahti AC, Tamminga CA. Probing the human hippocampus using rCBF: contrasts in schizophrenia. Hippocampus 2001;11:543-50 (Pubitemid 33100375)
77. Dawson N, Morris BJ, Pratt JA. Subanaesthetic ketamine treatment alters prefrontal cortex connectivity with thalamus and ascending subcortical systems. Schizophr Bull 2011;sbr144 [pii];10.1093/schbul/sbr144 [doi]
78. Bifone A, Gozzi A, Schwarz AJ. Functional connectivity in the rat brain: a complex network approach. Magn Reson Imag 2010;28:1200-9
79. Schwarz AJ, Gozzi A, Reese T, Bifone A. Functional connectivity in the pharmacologically activated brain: resolving networks of correlated responses to d-amphetamine. Magn Reson Med 2007;57:704-13 (Pubitemid 46731796)
80. Schwarz AJ, Gozzi A, Bifone A. Community structure in networks of functional connectivity: resolving functional organization in the rat brain with pharmacological MRI. Neuroimage 2009;47:302-11
81. Lu H, Zou Q, Gu H, et al. Rat brains also have a default mode network. PNAS 2012;109:3979-84
82. Schwarz AJ, Gozzi A, Chessa A, Bifone A. Voxel scale complex networks of functional connectivity in the rat brain: neurochemical state dependence of global and local topological properties. Comput Math Methods Med 2012;2012:Article ID 615709
83. Schwarz AJ, Gozzi A, Bifone A. Community structure and modularity in networks of correlated brain activity. Magn Reson Imaging 2008;26:914-20
84. Vollenweider FX, Kometer M. The neurobiology of psychedelic drugs: implications for the treatment of mood disorders. Nat Rev Neurosci 2010;11:642-51
85. Homayoun H, Moghaddam B. NMDA receptor hypofunction produces opposite effects on prefrontal cortex interneurons and pyramidal neurons. J Neurosci 2007;27:11496-500 (Pubitemid 350006886)
86. Greene R. Circuit analysis of NMDAR hypofunction in the hippocampus, in vitro, and psychosis of schizophrenia. Hippocampus 2001;11:569-77 (Pubitemid 33100377)